Fast Five Quiz: Coronary Artery Atherosclerosis

Yasmine S. Ali, MD


November 11, 2019

According to the 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes, when oral anticoagulation is initiated in a patient with chronic coronary syndrome and AF who is eligible for a NOAC, a NOAC is preferred over a VKA. Long-term oral anticoagulant therapy is recommended in patients with chronic coronary syndrome and AF and a CHA2DS2-VASc score ≥ 2 in males and ≥ 3 in females.

ESC guidelines also state that nitrates are not recommended for patients with hypertrophic obstructive cardiomyopathy or coadministration of phosphodiesterase inhibitors. Statins are recommended in all patients with chronic coronary syndromes. If goals are not achieved with the maximum tolerated dose of a statin, combination with ezetimibe is recommended. For patients at very high risk who do not achieve goals on a maximum tolerated dose of statin and ezetimibe, combination with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is recommended. First-line treatment for angina/ischemia relief in patients with chronic coronary syndromes is beta-blockers and/or calcium-channel blockers.

Read more about the treatment of coronary artery atherosclerosis and related conditions.

This Fast Five Quiz was excerpted and adapted from the Medscape Drugs & Diseases articles Coronary Artery Atherosclerosis and Risk Factors for Coronary Artery Disease.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: